LEXINGTON, Massachusetts, United States – May 6, 2026
Partner Therapeutics has announced that the U.S. Food and Drug Administration (FDA) awarded a Commissioner’s National Priority Voucher (CNPV) for BIZENGRI® (zenocutuzumab-zbco) for the treatment of adults with advanced, unresectable, or metastatic cholangiocarcinoma harboring neuregulin 1 (NRG1) gene fusions following progression after prior systemic therapy. The voucher was granted under the FDA’s newly established pilot program designed to accelerate review timelines for breakthrough therapies targeting major unmet medical needs. The recognition significantly strengthens the regulatory outlook for BIZENGRI®, a first-in-class bispecific antibody developed for patients with ultra-rare NRG1 fusion-positive cancers, where no approved targeted therapies currently exist.
FDA Voucher Accelerates Regulatory Review Process
The FDA’s Commissioner’s National Priority Voucher pilot program, launched in 2025, is intended to reduce drug review timelines from the standard 10–12 months to as little as 1–2 months for therapies aligned with key national healthcare priorities. The program prioritizes innovative treatments demonstrating novel mechanisms of action and significant clinical benefit in diseases with limited therapeutic options.
BIZENGRI® qualified for the accelerated review pathway due to its status as a first-in-class bispecific antibody targeting NRG1 fusion-driven tumors, a rare but actionable oncogenic driver associated with aggressive cancers and poor outcomes. Partner Therapeutics previously received both Breakthrough Therapy Designation and Orphan Drug Designation from the FDA for BIZENGRI® in NRG1-positive cholangiocarcinoma, further reinforcing regulatory support for the program.
Phase 2 eNRGy Trial Showed Promising Clinical Activity
Advertisement
The company submitted a supplemental Biologics License Application (sBLA) based on results from the Phase 2 eNRGy clinical trial, which evaluated zenocutuzumab in patients with NRG1 fusion-positive cancers. Clinical data presented at the AACR-NCI-EORTC Meeting in October 2025 demonstrated encouraging efficacy in patients with NRG1-positive cholangiocarcinoma, including objective tumor responses in more than one-third of evaluable patients and a median progression-free survival exceeding nine months.
Investigators also reported a favorable tolerability profile, supporting the therapy’s potential as a targeted treatment option for patients with limited alternatives. Researchers emphasized that the findings highlight the growing importance of comprehensive genomic profiling, particularly RNA-based molecular testing, to identify patients who may benefit from emerging precision oncology therapies.
Ultra-Rare Cholangiocarcinoma Represents Major Unmet Need
Cholangiocarcinoma, or bile duct cancer, remains one of the most difficult gastrointestinal cancers to treat, particularly in advanced stages where survival rates remain poor. The subset of patients harboring NRG1 gene fusions represents an ultra-rare molecularly defined population with virtually no approved targeted treatment options currently available.
Patient advocacy organizations and clinicians have increasingly emphasized the need for broader molecular testing to improve identification of rare genomic alterations that could guide targeted treatment strategies. The Cholangiocarcinoma Foundation stated that the FDA’s recognition underscores both the urgent unmet medical need and the importance of expanding access to biomarker testing to ensure patients can access personalized therapies earlier in their treatment journey.
BIZENGRI Expands Precision Oncology Landscape
BIZENGRI® represents part of the broader shift toward precision oncology and biomarker-driven cancer therapies, where treatments are developed specifically for patients carrying defined genetic alterations. As targeted therapies continue transforming cancer treatment, ultra-rare genomic subsets such as NRG1 fusions are increasingly becoming viable commercial and clinical opportunities for biotechnology companies.
The FDA’s accelerated support through the CNPV program may position Partner Therapeutics competitively within the rapidly growing precision medicine market while potentially bringing an urgently needed therapy to patients significantly faster than traditional review timelines.
Source: Partner Therapeutics press release
